|
| |
Image Results
Loading...
Loading...
Rebif Pages on BioPortfolio:
Rebif Beats Avonex In Head-To-Head Trial
Rebif is approved in over 70 countries, but had not been marketed in the U.S. ... As both Rebif and Avonex will now compete in the U.S., Rebif's advantage ...
http://www.bioportfolio.com/news/btech_041802_2.htm...
|
BioPortfolio Biotechnology BioNews : live article
During 2006, combined sales estimates of FDA-approved injectable MS therapies, which include Avonex®, Betaseron®, Copaxone®, and Rebif®, ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...
|
Biotech Tracker News - Suboptimal Study Suggests Rebif Advantage ...
26 Nov 2002 ... Therefore, these analyses are not likely to benefit Rebif strongly, although they also will not shift momentum back towards Avonex. ...
http://www.bioportfolio.com/news/biotracker_30.htm...
|
Results from other life science and pharmaceutical sites:
|